Prelude Capital Management, LLC Castle Biosciences Inc Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.19 - $22.43 $148,632 - $273,488	12,193 New	12,193 $263,000
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $1,935 - $2,951	86 Added 0.37%	23,144 $604,000
Q2 2022 Aug 15, 2022	BUY	$16.0 - $45.99 $249,456 - $717,030	15,591 Added 208.8%	23,058 $506,000
Q1 2022 May 16, 2022	BUY	$33.17 - $46.98 $53,470 - $75,731	1,612 Added 27.53%	7,467 $335,000
Q4 2021 Feb 14, 2022	BUY	$39.06 - $67.58 $27,615 - $47,779	707 Added 13.73%	5,855 $251,000
Q3 2021 Nov 15, 2021	BUY	$60.13 - $77.6 $300 - $388	5 Added 0.1%	5,148 $342,000
Q2 2021 Aug 16, 2021	BUY	$50.07 - $76.78 $257,510 - $394,879	5,143 New	5,143 $377,000
Q1 2020 May 15, 2020	SELL	$23.08 - $35.53 $556,251 - $856,308	-24,101 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$18.09 - $27.92 $435,987 - $672,899	24,101 New	24,101 $436,000

171

25.5M

511K

130K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $750M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.